Figure 3From: Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France Additional individual direct drug costs attributable to T2DM by treatment phase and resource category in 2010. *% calculated by treatment line; ex: additionnal drug costs in monotherapy = 28% antidiabetics, 51% cardiovascular system, 7% nervous system 7% blood and blood forming organs, 7% others. Back to article page